Giuseppe
Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
Pharmacokinetics of orally administered oseltamivir in healthy obese and non-obese Thai subjects
Podjanee Jittamala 1,3⇑, Sasithon Pukrittayakamee 3, Joel Tarning 1,2, Niklas Lindegardh 1,2, Warunee Hanpithakpong 2, Walter Robert John Taylor 2, Saranath Lawpoolsri 3, Prakaykaew Charunwattana 1,3, Salwaluk Panapipat 2, Nicholas J White 1,2 and Nicholas P J Day 1,2
Author Affiliations: <SUP>1</SUP>Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok Thailand. <SUP>2</SUP>Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. <SUP>3</SUP>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Published ahead of print 23 December 2013, doi: 10.1128/AAC.01786-13 <CITE>AAC.01786-13 </CITE>
<CITE></CITE>
<CITE></CITE>
<CITE></CITE>ABSTRACT
Objective
Oseltamivir is the most widely used anti-influenza drug. In the H1N1 2009 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavourable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and non-obese healthy subjects.
Method
A single-dose randomized, two sequence cross-over study was conducted in 12 obese and 12 non-obese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening wash-out period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a non-compartmental approach.
Results
The median (range) BMI for obese subjects was 33.8 kg/m<SUP>2</SUP> (30.8?43.2) and 22.2 (18.8?24.2) for non-obese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and non-obese subjects for both 75 mg and 150 mg doses.
Conclusions
Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects there was no significant difference in the exposure of oseltamivir carboxylate between the obese and non-obese group. Standard dosing is appropriate for obese subjects.
FOOTNOTES
Author for correspondence: Podjanee Jittamala, Mahidol Oxford Tropical Medicine Research Unit., 3/F 60<SUP>th</SUP> Anniversary Chalermprakiat Building., 420/6 Rajvithi road, Rajthevee, Bangkok 10400, Thailand, Tel: +66819563371, E mail: podjanee@tropmedres.ac
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
------
Pharmacokinetics of orally administered oseltamivir in healthy obese and non-obese Thai subjects
Podjanee Jittamala 1,3⇑, Sasithon Pukrittayakamee 3, Joel Tarning 1,2, Niklas Lindegardh 1,2, Warunee Hanpithakpong 2, Walter Robert John Taylor 2, Saranath Lawpoolsri 3, Prakaykaew Charunwattana 1,3, Salwaluk Panapipat 2, Nicholas J White 1,2 and Nicholas P J Day 1,2
Author Affiliations: <SUP>1</SUP>Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok Thailand. <SUP>2</SUP>Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. <SUP>3</SUP>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Published ahead of print 23 December 2013, doi: 10.1128/AAC.01786-13 <CITE>AAC.01786-13 </CITE>
<CITE></CITE>
<CITE></CITE>
<CITE></CITE>ABSTRACT
Objective
Oseltamivir is the most widely used anti-influenza drug. In the H1N1 2009 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavourable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and non-obese healthy subjects.
Method
A single-dose randomized, two sequence cross-over study was conducted in 12 obese and 12 non-obese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening wash-out period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a non-compartmental approach.
Results
The median (range) BMI for obese subjects was 33.8 kg/m<SUP>2</SUP> (30.8?43.2) and 22.2 (18.8?24.2) for non-obese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and non-obese subjects for both 75 mg and 150 mg doses.
Conclusions
Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects there was no significant difference in the exposure of oseltamivir carboxylate between the obese and non-obese group. Standard dosing is appropriate for obese subjects.
FOOTNOTES
Author for correspondence: Podjanee Jittamala, Mahidol Oxford Tropical Medicine Research Unit., 3/F 60<SUP>th</SUP> Anniversary Chalermprakiat Building., 420/6 Rajvithi road, Rajthevee, Bangkok 10400, Thailand, Tel: +66819563371, E mail: podjanee@tropmedres.ac
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
------